Steve Y. Cho, MD
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Chair, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Adjunct Faculty, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland
Education & Training
Degree-Granting Education
| 1995 | New York University School of Medicine, New York, New York, US, Doctor of Medicine (M.D.) |
| 1991 | Johns Hopkins University, Baltimore, Maryland, US, Bachelor of Arts (B.A.) |
Postgraduate Training
| 2006-2007 | PET/CT Clinical Fellowship, Johns Hopkins Hospital, Baltimore, Maryland |
| 2004-2006 | Nuclear Medicine Residency, Johns Hopkins Hospital, Baltimore, Maryland |
| 2001-2004 | Clinical Pharmacology Research Training Program (ClinPRAT), National Institutes of Health, Bethesda, Maryland |
| 1998-2001 | Pediatric Hematology/Oncology Clinical Fellowship, Johns Hopkins Hospital, Baltimore, Maryland |
| 1995-1998 | Pediatrics Internship and Residency, Johns Hopkins Hospital, Baltimore, Maryland |
Licenses & Certifications
| 2025 | TX Medical License |
| 2014 | WI Medical License |
Experience & Service
Faculty Academic Appointments
Professor, Department of Radiology, Nuclear Medicine and Molecular Imaging, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2021 - 2025
Associate Professor, Department of Radiology, Nuclear Medicine and Molecular Imaging, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2014 - 2021
Assistant Professor, Johns Hopkins University School of Medicine, Baltimore, Maryland, 2009 - 2014
Assistant Professor, Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 2007 - 2014
Administrative Appointments/Responsibilities
Director, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2022 - 2025
Section Chief, Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2021 - 2025
Associate Section Chief, Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2019 - 2021
ACGME Program Director, University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, 2019 - 2025
Associate Program Director, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2017 - 2019
Director, Department of Radiology, UWSMPH, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin, 2016 - 2025
Director, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2016 - 2025
Associate Director, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2014 - 2025
Co-Director, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, 2014 - 2016
Professional Memberships
Selected Presentations & Talks
Regional Presentations
- 2025. Prostate Cancer PSMA PET Imaging and Theranostics: Current Status and Future Developments. Invited. Wisconsin Radiological Society 2025 Annual Conference. Kohler, Wisconsin, US.
- 2024. PSMA PET and New Agents for Prostate Cancer. Invited. 2024 Central Chapter Society of Nuclear Medicine and Molecular Imaging’s Fall Education Program. Wisconsin Dells, Wisconsin, US.
- 2023. Theranostics: Current Status and Emerging Trends. Invited. UW Carbone Cancer Center Grand Rounds. Madison, Wisconsin, US.
- 2023. PSMA PET Imaging for Prostate Cancer in 2023. Invited. Wisconsin Urological Society 2023 Annual Meeting. Milwaukee, Wisconsin, US.
- 2016. Prostate Cancer Imaging - Emerging Imaging Radiotracers and Modalities; Impact of Nuclear Medicine from the Clinicians Perspective. Invited. CCSNMMI 2016 Annual Spring Meeting. Milwaukee, Wisconsin, US.
National Presentations
- 2025. Multimodality External Beam and Radiopharmaceutical Radiation Rationale and Applications. Invited. SNMMI 2025 Annual Meeting. New Orleans, Louisiana, US.
- 2024. Theranostics - Current Status and Emerging Developments. Invited. Inaugural Frontiers in Cancer Scientific Symposium. Hempstead, New York, US.
- 2023. Building a Clinical Translational Theranostics Team. Invited. SNMMI Fall Therapeutics Conference. Baltimore, Maryland, US.
- 2023. Theranostics and Molecular Imaging: Why all the excitement and where are we headed?. Invited. Cleveland, Ohio, US.
- 2023. Cardiac Sarcoidosis. Invited. SNMMI Correlative Imaging Council (CIC) Case Presentation. Virtual, US.
- 2022. Prostate PSMA Directed Theranostics and Patient Selection: Current US Perspective and Future Directions. Invited. World Federation of Nuclear Medicine and Biology 2022 Meeting. Virtual, US.
- 2022. Physicians in the Era of Artificial Intelligence: Collaborators and Users. Invited. SNMMI 2022 Annual Meeting. Vancouver, CA.
- 2022. Prostate PSMA Directed Theranostics: Patient Selection. Invited. SNMMI 2022 Annual Meeting. Vancouver, CA.
- 2022. PSMA PET Imaging for Prostate Cancer: Current and Future Applications. Invited. Virtual, US.
- 2022. Development of Prostate Cancer PET Imaging: Focus on PSMA; Session: Prostate Cancer: Imaging and Therapy – Where does Nuclear Medicine Fit. Invited. American Pharmacists Association 2022 Annual Meeting. Virtual, US.
Grant & Contract Support
| Date: | 2023 - 2027 |
| Title: | Multimodal Learning for Contextually-Aware Longitudinal PET/CT image analysis |
| Funding Source: | N/A |
| Role: | Co-I |
| ID: | 1R01EB033782-01A1 |
| Date: | 2022 - 2026 |
| Title: | An Integrative Radiogenomic Framework for Predicting Treatment Failure in Children, Adolescents & Young Adults with Hodgkin Lymphoma |
| Funding Source: | N/A |
| Role: | Co-PI |
| ID: | W81XWH-22-1-0337 (CA210872P1) |
| Date: | 2022 - 2025 |
| Title: | Phase II Evaluation of 18F-DCFPYL PSMA PET/MRI to Detect Prostate Cancer in Men Under Active-Surveillance |
| Funding Source: | N/A |
| Role: | PI |
| ID: | AAK4253 |
| Date: | 2021 - 2025 |
| Title: | Functional Lung Imaging Using a Single kV CT Acquisition |
| Funding Source: | N/A |
| Role: | Co-I |
| ID: | R01HL153594 |
| Date: | 2020 - 2025 |
| Title: | Evaluation of Prostate Specific Membrane Antigen (PSMA) in HER2-Negative, Androgen Receptor (AR)-Positive Metastatic Breast Cancer 18F-DCFPYL PSMA-Based PET/CT |
| Funding Source: | N/A |
| Role: | PI |
| ID: | AAI6428 |
Selected Publications
Peer-Reviewed Articles
- Huang, W, Li, H, Tsourkas, P, Mcilwain, S, Ong, IM, Kyriakopoulos, CE, Johnson, B, Cho, SY, Wells, S, Alzate, AR, Jarrard, DF, Heninger, E, Lang, JM. Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach. Journal of Pathology Informatics 19, 2025. e-Pub 2025. PMID: 41438589.
- Steimle AK, Cho SY, Menon N, Jeraj R, Birbrair A, Albertini MR, Ma VT. ctDNA Dynamics Identifies Pseudoprogression in a Metastatic Melanoma Patient Treated With Nivolumab/Relatlimab. J Immunother 48(8):325-328, 2025. e-Pub 2025. PMID: 40631532.
- Belsky JA, Renfro LA, Keller FG, Hodgson DC, Punnett A, McCarten K, Cho SY, Wu Y, Kelly KM, Castellino SM, Schwartz CL. Evaluation of the Childhood Hodgkin International Prognostic Score (CHIPS) in High-Risk Pediatric Hodgkin Lymphoma Patients Treated on Children's Oncology Group AHOD1331. Pediatr Blood Cancer 72(9):e31856, 2025. e-Pub 2025. PMID: 40515508.
- Floberg JM, Kyriakopoulos CE, Cho SY. Advanced Image Analysis to Select Patients for Prostate Specific Membrane Antigen Radioligand Therapy and Assess Treatment Response. Adv Radiat Oncol 10(8):101805, 2025. e-Pub 2025. PMID: 40697966.
- Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, Castellino SM, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Using a Longitudinally Aware Segmentation Network. Radiol Artif Intell 7(3):e240229, 2025. e-Pub 2025. PMID: 39969278.
- Santoro-Fernandes V, Schott B, Weisman AJ, Lokre O, Cho SY, Perlman SB, Perk TG, Jeraj R. Full-Body Tumor Response Heterogeneity of Metastatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radiopharmaceutical Therapy. J Nucl Med 66(4):565-571, 2025. e-Pub 2025. PMID: 39947917.
- Bruce JY, Burr A, Kimple RJ, Adam DP, Yu M, Piaskowski SM, Glazer TA, Hill P, Hartig GK, McCulloch TM, Wieland AM, Trask D, Oliver K, Longcor J, Rogus-Pulia N, Cho SY, Bednarz B, Harari PM. Safety and toxicity of Iopofosine I 131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: results of a phase 1 single-centre, open-label, single-arm, dose escalation and dose expansion study. EBioMedicine 111:105496, 2025. e-Pub 2025. PMID: 39671752.
- Stoevesandt D, Steglich J, Bartelt JM, Kurch L, McCarten KM, Flerlage JE, Georgi TW, Mauz-Korholz C, Cho SY, Korholz D, Kluge R, Kelly KM, Pelz T, Vordermark D, Hoppe BS, Dieckmann K, Voss SD. CT, MRI, and FDG PET/CT in the Assessment of Lymph Node Involvement in Pediatric Hodgkin Lymphoma: An Expert Consensus Definition by an International Collaboration on Staging Evaluation and Response Criteria Harmonization for Children, Adolescent, and Young Adult Hodgkin Lymphoma (SEARCH for CAYAHL). Radiology 314(1):e232650, 2025. e-Pub 2025. PMID: 39835977.
- Tie X, Shin M, Lee C, Perlman SB, Huemann Z, Weisman AJ, Castellino SM, Kelly KM, McCarten KM, Alazraki AL, Hu J, Cho SY, Bradshaw TJ. Automatic Quantification of Serial PET/CT Images for Pediatric Hodgkin Lymphoma Patients Using a Longitudinally-Aware Segmentation Network. ArXiv, 2024. e-Pub 2024. PMID: 38659641.
- Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho SY, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 22(6):413-433, 2024. e-Pub 2024. PMID: 39151455.
- Adam DP, Grudzinski JJ, Marsh IR, Hill PM, Cho SY, Bradshaw TJ, Longcor J, Burr A, Bruce JY, Harari PM, Bednarz BP. Voxel-Level Dosimetry for Combined Iodine 131 Radiopharmaceutical Therapy and External Beam Radiation Therapy Treatment Paradigms for Head and Neck Cancer. Int J Radiat Oncol Biol Phys 119(4):1275-1284, 2024. e-Pub 2024. PMID: 38367914.
- Yousefirizi F, Klyuzhin IS, O JH, Harsini S, Tie X, Shiri I, Shin M, Lee C, Cho SY, Bradshaw TJ, Zaidi H, Benard F, Sehn LH, Savage KJ, Steidl C, Uribe CF, Rahmim A. TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET/CT images - a multi-center generalizability analysis. Eur J Nucl Med Mol Imaging 51(7):1937-1954, 2024. e-Pub 2024. PMID: 38326655.
- Hayashi RJ, Hermiston ML, Wood BL, Teachey DT, Devidas M, Chen Z, Annett RD, Asselin BL, August K, Cho SY, Dunsmore KP, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju A, Lam A, Messinger YH, Miles RR, Okada M, Patel S, Schafer ES, Schechter T, Shimano KA, Singh N, Steele A, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay PA, Loh ML, Hunger SP, Raetz EA, Bollard CM, Allen CE. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231. Blood 143(20):2053-2058, 2024. e-Pub 2024. PMID: 38457359.
- Tie X, Shin M, Pirasteh A, Ibrahim N, Huemann Z, Castellino SM, Kelly KM, Garrett J, Hu J, Cho SY, Bradshaw TJ. Personalized Impression Generation for PET Reports Using Large Language Models. J Imaging Inform Med 37(2):471-488, 2024. e-Pub 2024. PMID: 38308070.
- Sadowski EA, Lees B, McMillian AB, Kusmirek JE, Cho SY, Barroilhet LM. Distribution of prostate specific membrane antigen (PSMA) on PET-MRI in patients with and without ovarian cancer. Abdom Radiol (NY) 48(12):3643-3652, 2023. e-Pub 2023. PMID: 37261441.
- Huemann Z, Lee C, Hu J, Cho SY, Bradshaw TJ. Domain-adapted Large Language Models for Classifying Nuclear Medicine Reports. Radiol Artif Intell 5(6):e220281, 2023. e-Pub 2023. PMID: 38074793.
- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer 70 Suppl 6(Suppl 6):e30580, 2023. e-Pub 2023. PMID: 37505794.
- Floberg JM, Wells SA, Ojala D, Bayliss RA, Hill PM, Morris BA, Morris ZS, Ritter M, Cho SY. Using (18)F-DCFPyL Prostate-Specific Membrane Antigen-Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy. Adv Radiat Oncol 8(5):101241, 2023. e-Pub 2023. PMID: 37250282.
- Hoppe BS, McCarten KM, Pei Q, Kessel S, Alazraki A, Mhlanga JC, Lai HA, Eutsler E, Hodgson DC, Roberts KB, Charpentier AM, Keller FG, Voss SD, Wu Y, Cho SY, Kelly KM, Castellino SM. Importance of Central Imaging Review in a Pediatric Hodgkin Lymphoma Trial Using Positron Emission Tomography Response Adapted Radiation Therapy. Int J Radiat Oncol Biol Phys 116(5):1025-1030, 2023. e-Pub 2023. PMID: 36868525.
- Lo AC, Lee I, Pei Q, Wu Y, McCarten KM, Hoppe BS, Hodgson DC, Roberts K, Milgrom S, Kessel S, Cole PD, Kelly KM, Cho SY. Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831. Pediatr Blood Cancer 70(8):e30452, 2023. e-Pub 2023. PMID: 37243975.
- Mhlanga J, Alazraki A, Cho SY, Lai H, Nadel H, Pandit-Taskar N, Qi J, Rajderkar D, Voss S, Watal P, McCarten K. Imaging recommendations in pediatric lymphoma: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatr Blood Cancer 70 Suppl 4(Suppl 4):e29968, 2023. e-Pub 2023. PMID: 36114654.
- Milgrom SA, Kim J, Pei Q, Lee I, Hoppe BS, Wu Y, Hodgson D, Kessel S, McCarten KM, Roberts K, Lo AC, Cole PD, Kelly KM, Cho SY. Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group study. Br J Haematol 201(6):1192-1199, 2023. e-Pub 2023. PMID: 36922022.
- Fendler WP, Eiber M, Beheshti M, Bomanji J, Calais J, Ceci F, Cho SY, Fanti S, Giesel FL, Goffin K, Haberkorn U, Jacene H, Koo PJ, Kopka K, Krause BJ, Lindenberg L, Marcus C, Mottaghy FM, Oprea-Lager DE, Osborne JR, Piert M, Rowe SP, Schoder H, Wan S, Wester HJ, Hope TA, Herrmann K. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. Eur J Nucl Med Mol Imaging 50(5):1466-1486, 2023. e-Pub 2023. PMID: 36604326.
- Lawrence EM, Kieler M, Cooley G, Wells SA, Cho SY. Assessment of 18F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability. PLoS One 18(4):e0283830, 2023. e-Pub 2023. PMID: 37023049.
- Castellino SM, Pei Q, Parsons SK, Hodgson D, McCarten K, Horton T, Cho S, Wu Y, Punnett A, Dave H, Henderson TO, Hoppe BS, Charpentier AM, Keller FG, Kelly KM. Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin's Lymphoma. N Engl J Med 387(18):1649-1660, 2022. e-Pub 2022. PMID: 36322844.
- Parekh A, Keller FG, McCarten KM, Kessel S, Cho S, Pei Q, Wu Y, Castellino SM, Constine LS, Schwartz CL, Hodgson D, Kelly KM, Hoppe BS. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood 140(10):1086-1093, 2022. e-Pub 2022. PMID: 35763667.
- Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol 40(19):2106-2118, 2022. e-Pub 2022. PMID: 35271306.
- Grudzinski JJ, Hall LT, Cho S, Liu G, Traynor A, Lee MH, Longino M, Pinchuk A, Jaskowiak C, Bednarz B, Weichert J, Kuo JS. Clinical Imaging and Dosimetry of a Pan- Cancer Targeting Alkylphosphocholine Analog, [124I]I-NM404. Radiation 2(2):215–227, 2022. e-Pub 2022.
- Parikh RR, Kelly KM, Hodgson DC, Hoppe BS, McCarten KM, Karolczuk K, Pei Q, Wu Y, Cho SY, Schwartz C, Cole PD, Roberts K. Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 112(4):890-900, 2022. e-Pub 2022. PMID: 34767937.
- Zukotynski KA, Emmenegger U, Hotte S, Kapoor A, Fu W, Blackford AL, Valliant J, Benard F, Kim CK, Markowski MC, Eisenberger MA, Antonarakis ES, Pienta KJ, Gorin MA, Lubanovic M, Kim J, Pomper MG, Cho SY, Rowe SP. Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen-Targeted (18)F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide. J Nucl Med 62(10):1430-1437, 2021. e-Pub 2021. PMID: 33608426.
- Milgrom SA, Kim J, Chirindel A, Kim J, Pei Q, Chen L, Buxton A, Kessel S, Leal J, McCarten KM, Hoppe BS, Wolden SL, Schwartz CL, Friedman DL, Kelly KM, Cho SY. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr Blood Cancer 68(9):e29212, 2021. e-Pub 2021. PMID: 34245210.
- Ng TSC, An BP, Cho SY, Hyun H. US Trainee and Faculty Perspectives on Exposure to Nuclear Medicine/Molecular Imaging During Medical School. Curr Probl Diagn Radiol 50(5):585-591, 2021. e-Pub 2021. PMID: 32653243.
- Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA. Diagnostic Performance of (18)F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res 27(13):3674-3682, 2021. e-Pub 2021. PMID: 33622706.
- Witt JS, Kuczmarska-Haas A, Lubner M, Reeder SB, Cho SY, Minter R, Weber S, Ronnekleiv-Kelly S, Abbott D, LoConte N, Mulkerin DL, Lubner SJ, Uboha NV, Deming D, Ritter MA, Mohindra P, Bassetti MF. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Int J Radiat Oncol Biol Phys 109(2):458-463, 2021. e-Pub 2021. PMID: 32942002.
- Geller JI, Pressey JG, Smith MA, Kudgus RA, Cajaiba M, Reid JM, Hall D, Barkauskas DA, Voss SD, Cho SY, Berg SL, Dome JS, Fox E, Weigel BJ. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer 126(24):5303-5310, 2020. e-Pub 2020. PMID: 32914879.
- Weisman AJ, Kim J, Lee I, McCarten KM, Kessel S, Schwartz CL, Kelly KM, Jeraj R, Cho SY, Bradshaw TJ. Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients. EJNMMI Phys 7(1):76, 2020. e-Pub 2020. PMID: 33315178.
- Zukotynski KA, Jadvar H, Potvin K, Cho SY, Kim CK, Winquist E. Prostate Cancer Lymphangitic Pulmonary Carcinomatosis: Appearance on 18F-FDG PET/CT and 18F-DCFPyL PET/CT. Clin Nucl Med 45(9):727-729, 2020. e-Pub 2020. PMID: 32520499.
- Hagleitner MM, Metzger ML, Flerlage JE, Kelly KM, Voss SD, Kluge R, Kurch L, Cho S, Mauz-Koerholz C, Beishuizen A. Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL). Pediatr Blood Cancer 67(8):e28365, 2020. e-Pub 2020. PMID: 32491274.
- Cho SY, Rowe SP, Jain SK, Schon LC, Yung RC, Nayfeh TA, Bingham CO 3rd, Foss CA, Nimmagadda S, Pomper MG. Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [(124)I]FIAU PET/CT. Mol Imaging 19:1536012120936876, 2020. e-Pub 2020. PMID: 32598214.
- Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, McCarten KM, Cho SY, Schwartz C. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. Br J Haematol 187(1):39-48, 2019. e-Pub 2019. PMID: 31180135.
- Rutkowski DR, Wells SA, Johnson B, Huang W, Jarrard DF, Lang JM, Cho S, Roldan-Alzate A. Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. Am J Clin Exp Urol 7(4):215-222, 2019. e-Pub 2019. PMID: 31511828.
- Ni D, Jiang D, Kutyreff CJ, Lai J, Yan Y, Barnhart TE, Yu B, Im HJ, Kang L, Cho SY, Liu Z, Huang P, Engle JW, Cai W. Molybdenum-based nanoclusters act as antioxidants and ameliorate acute kidney injury in mice. Nat Commun 9(1):5421, 2018. e-Pub 2018. PMID: 30575745.
- Perk T, Bradshaw T, Chen S, Im HJ, Cho S, Perlman S, Liu G, Jeraj R. Automated classification of benign and malignant lesions in (18)F-NaF PET/CT images using machine learning. Phys Med Biol 63(22):225019, 2018. e-Pub 2018. PMID: 30457118.
- Jiang D, Ge Z, Im HJ, England CG, Ni D, Hou J, Zhang L, Kutyreff CJ, Yan Y, Liu Y, Cho SY, Engle JW, Shi J, Huang P, Fan C, Yan H, Cai W. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng 2(11):865-877, 2018. e-Pub 2018. PMID: 30505626.
- Plyku D, Mena E, Rowe SP, Lodge MA, Szabo Z, Cho SY, Pomper MG, Sgouros G, Hobbs RF. Combined model-based and patient-specific dosimetry for (18)F-DCFPyL, a PSMA-targeted PET agent. Eur J Nucl Med Mol Imaging 45(6):989-998, 2018. e-Pub 2018. PMID: 29460025.
- Im HJ, Zhang Y, Wu H, Wu J, Daw NC, Navid F, Shulkin BL, Cho SY. Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. Radiology 287(1):303-312, 2018. e-Pub 2018. PMID: 29357275.
- Cho SY. Proposed Criteria Positions PSMA PET for the Future. J Nucl Med 59(3):466-468, 2018. e-Pub 2018. PMID: 29301930.
- Zukotynski KA, Valliant J, Benard F, Rowe SP, Kim CK, Pomper MG, Cho SY. Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. Clin Nucl Med 43(3):213-216, 2018. e-Pub 2018. PMID: 29356735.
- Im HJ, Solaiyappan M, Lee I, Bradshaw T, Daw NC, Navid F, Shulkin BL, Cho SY. Multi-level otsu method to define metabolic tumor volume in positron emission tomography. Am J Nucl Med Mol Imaging 8(6):373-386, 2018. e-Pub 2018. PMID: 30697457.
- Lee I, Im HJ, Solaiyappan M, Cho SY. Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma. EJNMMI Phys 4(1):22, 2017. e-Pub 2017. PMID: 28921170.
- Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, Chirindel A, Pardoll DM, Topalian SL, Wahl RL. Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point (18)F-FDG PET/CT Imaging in Patients with Advanced Melanoma. J Nucl Med 58(9):1421-1428, 2017. e-Pub 2017. PMID: 28360208.
- Jiang D, Im HJ, Sun H, Valdovinos HF, England CG, Ehlerding EB, Nickles RJ, Lee DS, Cho SY, Huang P, Cai W. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging 44(8):1296-1305, 2017. e-Pub 2017. PMID: 28265738.
- Flerlage JE, Kelly KM, Beishuizen A, Cho S, De Alarcon PA, Dieckmann U, Drachtman RA, Hoppe BS, Howard SC, Kaste SC, Kluge R, Kurch L, Landman-Parker J, Lewis J, Link MP, McCarten K, Punnett A, Stoevesandt D, Voss SD, Wallace WH, Mauz-Korholz C, Metzger ML. Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement. Pediatr Blood Cancer 64(7), 2017. e-Pub 2017. PMID: 28097818.
- Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, Giesel F, Haberkorn U, Hope TA, Kopka K, Krause BJ, Mottaghy FM, Schoder H, Sunderland J, Wan S, Wester HJ, Fanti S, Herrmann K. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44(6):1014-1024, 2017. e-Pub 2017. PMID: 28283702.
- England CG, Im HJ, Feng L, Chen F, Graves SA, Hernandez R, Orbay H, Xu C, Cho SY, Nickles RJ, Liu Z, Lee DS, Cai W. Re-assessing the enhanced permeability and retention effect in peripheral arterial disease using radiolabeled long circulating nanoparticles. Biomaterials 100:101-9, 2016. e-Pub 2016. PMID: 27254470.
- Im HJ, England CG, Feng L, Graves SA, Hernandez R, Nickles RJ, Liu Z, Lee DS, Cho SY, Cai W. Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. ACS Appl Mater Interfaces 8(28):17955-63, 2016. e-Pub 2016. PMID: 27340833.
- England CG, Kamkaew A, Im HJ, Valdovinos HF, Sun H, Hernandez R, Cho SY, Dunphy EJ, Lee DS, Barnhart TE, Cai W. ImmunoPET Imaging of Insulin-Like Growth Factor 1 Receptor in a Subcutaneous Mouse Model of Pancreatic Cancer. Mol Pharm 13(6):1958-66, 2016. e-Pub 2016. PMID: 27054683.
- Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, Eisenberger M, Carducci M, Fan H, Dannals RF, Chen Y, Mease RC, Szabo Z, Pomper MG, Cho SY. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. Mol Imaging Biol 18(3):411-9, 2016. e-Pub 2016. PMID: 27080322.
- Zhang XM, Zhang HH, McLeroth P, Berkowitz RD, Mont MA, Stabin MG, Siegel BA, Alavi A, Barnett TM, Gelb J, Petit C, Spaltro J, Cho SY, Pomper MG, Conklin JJ, Bettegowda C, Saha S. [(124)I]FIAU: Human dosimetry and infection imaging in patients with suspected prosthetic joint infection. Nucl Med Biol 43(5):273-9, 2016. e-Pub 2016. PMID: 27150029.
- Rowe SP, Macura KJ, Ciarallo A, Mena E, Blackford A, Nadal R, Antonarakis ES, Eisenberger MA, Carducci MA, Ross AE, Kantoff PW, Holt DP, Dannals RF, Mease RC, Pomper MG, Cho SY. Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer. J Nucl Med 57(1):46-53, 2016. e-Pub 2016. PMID: 26493203.
- Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, Cho SY, Pomper MG, Allaf ME. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (1)(8)F-DCFPyL PET/CT. Ann Nucl Med 29(10):877-82, 2015. e-Pub 2015. PMID: 26286635.
- Rowe SP, Deville C, Paller C, Cho SY, Fishman EK, Pomper MG, Ross AE, Gorin MA. Uptake of (18)F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. Tomography 1(2):81-84, 2015. e-Pub 2015. PMID: 26807444.
- Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG. Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. Mol Imaging Biol 17(4):565-74, 2015. e-Pub 2015. PMID: 25896814.
- Walker AJ, Chirindel A, Hobbs RF, Huynh-Le MP, Moore JA, Cho SY, Terezakis SA. Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma. Pract Radiat Oncol 5(4):219-27, 2015. e-Pub 2015. PMID: 26146182.
- Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY. (1)(8)F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med 56(7):1003-1010, 2015. e-Pub 2015. PMID: 26069305.
- Bradshaw TJ, Cho SY, Jaskowiak C, Wollenweber S, Jeraj R, Perlman SB. Clinical impact of a commercial data-driven PET respiratory gating method. EJNMMI Research (resubmitted 11/2020).
Review Articles
- Oh C, Bishop MW, Cho SY, Im HJ, Shulkin BL. (18)F-FDG PET/CT in the Management of Osteosarcoma. J Nucl Med 64(6):842-851, 2023. e-Pub 2023. PMID: 37201958.
- Fowler AM, Cho SY. PET Imaging for Breast Cancer. Radiol Clin North Am 59(5):725-735, 2021. e-Pub 2021. PMID: 34392915.
- Cho SY, Huff DT, Jeraj R, Albertini MR. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Semin Nucl Med 50(6):518-531, 2020. e-Pub 2020. PMID: 33059821.
- McCarten KM, Nadel HR, Shulkin BL, Cho SY. Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. Pediatr Radiol 49(11):1545-1564, 2019. e-Pub 2019. PMID: 31620854.
- Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, Cho S, Zaidi H, Casey ME, Wahl RL. Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Imaging 46(2):501-518, 2019. e-Pub 2019. PMID: 30269154.
- Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current Methods to Define Metabolic Tumor Volume in Positron Emission Tomography: Which One is Better?. Nucl Med Mol Imaging 52(1):5-15, 2018. e-Pub 2018. PMID: 29391907.
- Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19(3):223-30, 2016. e-Pub 2016. PMID: 27136743.
- Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG. Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging 59(3):241-68, 2015. e-Pub 2015. PMID: 26213140.
Other Articles
- Ibrahim N, Cho SY Prostate cancer imaging: positron-emission tomography perspectives. Rep Med Imaging 8:51-62, 2015.
Editorials
- Cho SY. To Hold or Not to Hold Metformin for FDG PET Scans: That Is the Question. Radiology 289(2):426-427, 2018. PMID: 30106340.
Book Chapters
- Cho SY, Macura K, Eisenberger M. New Imaging Modalities. In: Management of Castration Resistant Prostate Cancer. Humana Press, 2014.
- Cho SY, Pomper MG. Clinical Translation of Molecular Imaging Probes. In: Molecular Imaging Probes for Cancer Research. 1st. World Scientific Publishing, 2012.
- Cho SY, Pomper MG. Molecular Imaging in Prostate Cancer. In: Molecular Imaging in Oncology. Informa Health Care Press, 2008.
- Cho SY, Fine HA. Central Nervous System Malignancy and Clinical Pharmacology. In: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Humana Press, 373–393, 2004.
- Tsiagbe VK, Yoshimoto T, Asakawa J, Cho SY, Meruelo D, Thorbecke GJ. MTVencoded superantigen expression in B-Lymphoma cells in SJL mice as a stimulus for “Reversed Immunological Surveillance”. In: Superantigens: A Pathogen's View of the Immune System. Cold Spring Harbor Laboratory Press, 93-115, 1993.
Letters to the Editor
- Torres-Velazquez M, Parker M, Bo A, White M, Tanabe S, Pearce RA, Lennertz R, Cho SY, Bendlin B, Johnson SC, Prabhakaran V, McMillan AB, Sanders RD. Amyloid deposition on positron emission tomography correlates with severity of perioperative delirium: a case-control pilot study. Br J Anaesth 128: e226-e228, 2022.
Patient Reviews
CV information above last modified March 10, 2026